Empagliflozin (Jardiance) vs. Semaglutide (Wegovy): A Patient Guide
Empagliflozin (Jardiance) and Semaglutide (Wegovy) are both prescription medications that can improve health outcomes, but they work differently and are used for distinct primary purposes. Jardiance primarily helps manage heart failure and kidney disease, while Wegovy is mainly used for weight management and reducing cardiovascular risk in overweight or obese individuals. This guide will help you understand their key differences.
Side-by-Side Comparison
| Category | Empagliflozin | Semaglutide |
|---|---|---|
| Drug Class | SGLT2 Inhibitor | GLP-1 Receptor Agonist |
| Primary Use | Reducing risk of cardiovascular death and hospitalization for heart failure, and slowing kidney disease progression. | Weight management (alongside diet/exercise) and reducing major cardiovascular events in adults with established cardiovascular disease and obesity/overweight. |
| Mechanism of Action | Blocks glucose reabsorption in the kidneys, leading to glucose excretion in urine. | Mimics a natural hormone (GLP-1) to regulate appetite, slow stomach emptying, and improve blood sugar control. |
| Administration | Oral tablet, taken once daily. | Subcutaneous injection, typically once weekly. |
| Key Benefit (Beyond Primary Use) | Proven benefits for heart and kidney protection, even in those without diabetes. | Significant and sustained weight loss, with cardiovascular benefits. |
| Main Limitation/Warning | Risk of diabetic ketoacidosis (especially in Type 1 diabetes), urinary tract infections, and dehydration. | Risk of pancreatitis, gallbladder problems, and potential thyroid C-cell tumors (seen in animal studies). |
| When to Choose | A doctor might prefer Empagliflozin (Jardiance) if you have heart failure, chronic kidney disease, or Type 2 diabetes with established cardiovascular disease, to protect your heart and kidneys. It is a good option when the primary goal is to reduce hospitalizations for heart failure or slow the progression of kidney damage. | A doctor might prefer Semaglutide (Wegovy) if your primary health goal is significant weight loss, especially if you are overweight or obese and have weight-related health conditions. It is also a strong consideration for reducing major adverse cardiovascular events in individuals with established cardiovascular disease and obesity. |
| Side Effects | Empagliflozin's common side effects include urinary tract infections, yeast infections, and increased urination due to its kidney action. Semaglutide commonly causes gastrointestinal issues like nausea, vomiting, diarrhea, or constipation, especially when starting or increasing the dose. Both drugs have more serious, though less common, warnings that your doctor will discuss. | |
| Cost | Neither Empagliflozin (Jardiance) nor Semaglutide (Wegovy) are currently available as generic medications, meaning both are brand-name drugs and can be quite expensive. Insurance coverage varies widely, and out-of-pocket costs can be substantial. |
Bottom Line
Empagliflozin (Jardiance) and Semaglutide (Wegovy) are powerful medications with distinct benefits for heart, kidney, and metabolic health. Jardiance is a daily pill focused on heart failure and kidney protection, while Wegovy is a weekly injection primarily for weight loss and cardiovascular risk reduction. Your doctor will consider your specific health conditions, goals, and other medications to determine which, if either, is most appropriate for you.
Empagliflozin Overview
Empagliflozin (Jardiance) is a medication that helps your kidneys remove extra sugar from your body through urine. It is prescribed to treat type 2 diabetes by lowering blood sugar, and also helps reduce the risk of heart-related problems and hospitalizations in adults with heart failure or chronic kidney disease.
Full Empagliflozin guide →Semaglutide Overview
Semaglutide is a once-weekly (or once-daily oral) GLP-1 receptor agonist that lowers blood sugar and reduces body weight by mimicking the natural gut hormone GLP-1. It is sold under three brand names — Ozempic (injectable, type 2 diabetes), Wegovy (injectable, weight management), and Rybelsus (oral tablet, type 2 diabetes) — all manufactured by Novo Nordisk. Clinical trials show it reduces HbA1c by up to 2.0 percentage points and body weight by up to 15% at the highest injectable dose.
Full Semaglutide guide →Compare prices for Empagliflozin and Semaglutide
Check real-time pharmacy prices before you fill — free, no account needed.
Protect your muscle mass on GLP-1 medications
GLP-1 medications can cause up to 39% muscle loss alongside fat. Zova's AI-powered protocol — backed by Lancet Diabetes & Endocrinology research — reduces that to just 8.7% through leucine tracking and injection-day adaptive nutrition.
No credit card. No commitment.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.